Baudax Bio Inc. (BXRX) shares surged 6.32% in after-hours on Friday, October 29, 2021, and closed the weekly trading at $0.56. In the regular trading session of Friday, BXRX’s stock lost 7.74%. The stock volume remained 1.77 million shares, which was lower than the average daily volume of 2.87 million shares within the past 50 days. BXRX shares have fallen 53.81% over the last 12 months, and they have moved down 0.02% in the past week. Over the past three months, the stock has lost 15.87%, while over the past six months, it has declined 52.97%.
Let’s have a brief look at its recent news and developments.
BXRX upcoming financial results announcement
On October 28, 2021, Baudax Bio, Inc. (BXRX), announced that it will report third-quarter 2021 financial results on Thursday, November 4, 2021. The company will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021.
BXRX participation in the recent conferences
Baudax Bio, Inc (BXRX) recently participated at the NobleCon Pain Management Investor Forum which was held virtually on Thursday, October 7, 2021. The company’s management did a corporate presentation followed by a question-and-answer session at the event.
The company also took part in the H.C. Wainwright 23rd Annual Global Investment Conference, which was held virtually on September 13-15, 2021. The Company’s President and Chief Executive Officer, Gerri Henwood gave a corporate presentation during the event.
BXRX Inducement grants
On October 01, 2021, the Compensation Committee of Baudax Bio’s Board of Directors (BXRX) approved inducement grants of stock options to purchase an aggregate of 242,688 shares of Baudax Bio’s common stock and restricted stock units covering 79,385 shares of Baudax Bio’s common stock to 22 newly-hired employees, with a grant date of September 30, 2021.
Well, as of this writing there was no such news or development which could be linked with its mixed performance on Friday. we hope that it will commence the new trading week with positive energy.
About the company
Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. The company’s first commercialized product, ANJESO® (meloxicam) injection, was approved by the U.S. Food and Drug Administration (FDA) in February 2020. ANJESO is indicated for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs.